Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 4 2Phase 2 2Phase 2/3 1Phase 1 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Breast Neoplasms 1277Carcinoma, Non-Small-Cell Lung 926Prostatic Neoplasms 729Neoplasms 632Multiple Myeloma 553Lymphoma 539Colorectal Neoplasms 529Lung Neoplasms 515Leukemia 497Leukemia, Myeloid, Acute 472Neoplasm Metastasis 470Melanoma 425Lymphoma, Non-Hodgkin 417Ovarian Neoplasms 416Leukemia, Lymphocytic, Chronic, B-Cell 386Pancreatic Neoplasms 373Recurrence 335Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Head and Neck Neoplasms 306Lymphoma, Large B-Cell, Diffuse 294Glioblastoma 294Myelodysplastic Syndromes 287Brain Neoplasms 287Lymphoma, Follicular 286Stomach Neoplasms 280Carcinoma, Renal Cell 268Hodgkin Disease 261Carcinoma, Hepatocellular 261Rectal Neoplasms 256Sarcoma 250

Interventions

OM 89 1Mn-PyC3A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Multiple Sclerosis × Clear all
NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

Phase 2 Completed
18 enrolled
CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

NCT02591901 2020-03-18

PReSuTINeB

Buckinghamshire Healthcare NHS Trust

Phase 2 Completed
48 enrolled
Genitourinary

Urinary Bladder, Neurogenic, Multiple Sclerosis, Myelitis, Transverse, Spinal Cord Injuries, Urinary Tract Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡